Results 71 to 80 of about 112,157 (308)

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács   +8 more
wiley   +1 more source

Proteomic profiling of senescent human diploid fibroblasts treated with gamma-tocotrienol

open access: yesBMC Complementary and Alternative Medicine, 2018
Background Replicative senescence of human diploid fibroblasts (HDFs) has been used as a model to study mechanisms of cellular aging. Gamma-tocotrienol (γT3) is one of the members of vitamin E family which has been shown to increase proliferation of ...
Jen-Kit Tan   +2 more
doaj   +1 more source

Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells

open access: yesScientific Reports, 2022
Accumulation of senescent cells in various tissues has been reported to have a pathological role in age-associated diseases. Elimination of senescent cells (senolysis) was recently reported to reversibly improve pathological aging phenotypes without ...
Masayoshi Suda   +14 more
doaj   +1 more source

MicroRNAs in age-related diseases [PDF]

open access: yes, 2013
Aging is a complex process that is linked to an increased incidence of major diseases such as cardiovascular and neurodegenerative disease, but also cancer and immune disorders.
Jazbutyte V   +4 more
core   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson   +3 more
wiley   +1 more source

Therapeutic targeting of senescent cells in the CNS. [PDF]

open access: yesNat Rev Drug Discov
Riessland M   +4 more
europepmc   +2 more sources

mRNA methylation in cell senescence [PDF]

open access: yesWIREs RNA, 2019
AbstractCellular senescence, a developmental program central to normal aging and aging pathologies, is robustly regulated at the post‐transcriptional level. This regulation involves the interaction of RNA‐binding proteins and noncoding RNAs with senescence‐associated messenger RNAs (mRNAs).
Gabriel Casella   +3 more
openaire   +2 more sources

Evaluating the Utility of Paired Tumor and Germline Targeted DNA Sequencing for Pediatric Oncology Patients: A Single Institution Report

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate the diagnostic yield and utility of universal paired tumor–normal multigene panel sequencing in newly diagnosed pediatric solid and central nervous system (CNS) tumor patients and to compare the detection of germline pathogenic/likely pathogenic variants (PV/LPVs) against established clinical referral criteria for cancer ...
Natalie Waligorski   +9 more
wiley   +1 more source

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

open access: yesScientific Reports, 2021
A wide range of diseases have been shown to be influenced by the accumulation of senescent cells, from fibrosis to diabetes, cancer, Alzheimer’s and other age-related pathologies.
Marta Poblocka   +10 more
doaj   +1 more source

Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. [PDF]

open access: yes, 2015
Tyrosine kinase inhibitors (TKIs) including axitinib have been introduced in the treatment of renal cell carcinoma (RCC) because of their anti-angiogenic properties.
Amantini, C   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy